How Much Does Ozempic Cost in Minnesota in 2026?

Retail Cash Price at Minnesota Pharmacies

Ozempic (semaglutide injection) costs $998 per month at Minnesota retail pharmacies when purchased without insurance. That figure matches Novo Nordisk's national wholesale acquisition cost and applies uniformly across all four pen strengths: 0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg [1]. The price does not vary between Minneapolis, Duluth, Rochester, or rural pharmacies in any clinically meaningful way because the wholesale acquisition cost is set nationally by the manufacturer.

This $998 figure represents the pre-discount sticker price. Actual out-of-pocket cost depends on three variables: insurance formulary placement, copay assistance enrollment, and whether the prescriber documents the clinical rationale needed for prior authorization. According to the FDA-approved prescribing information for Ozempic, the drug is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [1]. Off-label weight-loss prescribing, while common, changes the insurance calculus significantly. Patients prescribed Ozempic off-label for obesity face higher denial rates and may pay full cash price.

A 2017 analysis in Diabetes Care found that average annual out-of-pocket costs for GLP-1 receptor agonists exceeded $2,000 even among insured patients, a figure that has only increased with list-price inflation since [2]. Minnesota residents paying cash should expect to spend approximately $11,976 per year before any discount programs.

Minnesota Insurance Coverage for Ozempic

Most major commercial plans in Minnesota cover Ozempic on a preferred or non-preferred specialty tier when prescribed for type 2 diabetes. Blue Cross Blue Shield of Minnesota, HealthPartners, Medica, and UnitedHealthcare all include semaglutide on their 2026 formularies, though tier placement and step-therapy requirements differ across plans.

Tier placement determines your copay. Preferred-brand placement typically means a $25 to $50 copay per 30-day supply. Non-preferred placement pushes that to $75 to $150. Some high-deductible health plans require patients to meet a $1,500 to $3,000 deductible before brand copay rates apply [3].

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists as second-line therapy after metformin for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, and as an option for patients prioritizing weight management [3]. This guideline language is directly referenced in most Minnesota payer prior-authorization criteria. Patients whose prescribers cite ADA Standards of Care language in PA submissions see higher approval rates.

Step therapy is the most common barrier. Several Minnesota plans require documentation of metformin trial (or intolerance) and an A1c at or above 7.0% before approving Ozempic. The SUSTAIN-7 trial demonstrated that semaglutide 0.5 mg reduced A1c by 1.5% and semaglutide 1.0 mg reduced A1c by 1.8% compared to dulaglutide over 40 weeks (N=1,201) [4]. This head-to-head data against another GLP-1 agonist gives prescribers strong clinical justification when appealing tier exceptions or step-therapy overrides.

Minnesota Medicaid and Ozempic

Minnesota Medical Assistance (the state's Medicaid program) covers Ozempic with prior authorization for adults with type 2 diabetes. The PA requirement is not a denial. It is a documentation gate.

To approve the PA, Minnesota Medicaid requires prescribers to document: a current A1c value, evidence that metformin was tried or is contraindicated, and a diagnosis of type 2 diabetes (ICD-10 E11.x). Off-label weight-management prescriptions are not covered under the standard Medicaid benefit. Patients enrolled in managed care organizations (MCOs) like UCare, Hennepin Health, or Blue Plus may encounter slightly different PA forms, but the clinical criteria remain consistent with the state's preferred drug list.

Processing time for PA submissions in Minnesota typically ranges from 24 to 72 hours. The Endocrine Society's 2022 clinical practice guideline on pharmacological management of obesity notes that GLP-1 receptor agonists produce "clinically meaningful weight loss and cardiovascular risk reduction beyond glycemic control" [5]. While this guideline supports broader use, Minnesota Medicaid limits coverage to the FDA-approved type 2 diabetes indication.

Dual-eligible patients (those enrolled in both Medicare and Medicaid) should note that Medicare Part D generally covers Ozempic for diabetes. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending, fully effective since 2025, may reduce costs for dual-eligible seniors who fill through the Part D benefit rather than Medicaid [6].

The Novo Nordisk Savings Card in Minnesota

Novo Nordisk offers a manufacturer savings card that reduces out-of-pocket cost to as low as $25 per 30-day fill for commercially insured patients. The card covers up to $150 per fill in copay assistance. It works at all Minnesota pharmacies that accept commercial insurance.

Eligibility rules are strict. Patients must have commercial insurance that covers Ozempic. The card does not apply to government-funded programs: Medicare, Medicaid, Tricare, VA benefits, and state-funded plans are excluded. Uninsured patients paying full cash price are also ineligible for this specific card, though Novo Nordisk operates a separate patient assistance program (PAP) for uninsured individuals with household income below 400% of the federal poverty level.

The savings card resets annually. Minnesota patients should re-enroll each January. Activation requires no medical documentation; patients register through the Novo Nordisk website or by calling the number on the card packaging. The benefit applies at point of sale, so pharmacists can process it immediately once the card's BIN and PCN numbers are entered.

Compounded Semaglutide in Minnesota

Compounded semaglutide is legal in Minnesota when dispensed by a licensed 503A compounding pharmacy operating under a valid patient-specific prescription. The price averages $199 per month, roughly 80% less than brand Ozempic.

The FDA's position on compounded semaglutide has shifted multiple times. Semaglutide appeared on the FDA drug shortage list, which permitted 503A and 503B compounders to produce copies under federal law. As of 2026, patients and prescribers should verify current shortage-list status before initiating compounded semaglutide, because removal from the shortage list restricts compounding rights.

Minnesota follows the federal framework for 503A pharmacy regulation. A 503A pharmacy in Minnesota may compound semaglutide if: the pharmacist holds a valid Minnesota Board of Pharmacy license, a patient-specific prescription exists, and the compounding occurs in response to a documented medical need. 503B outsourcing facilities operate under FDA oversight and may distribute without patient-specific prescriptions, but availability through 503B sources depends on current FDA enforcement decisions.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has stated: "Patients and clinicians need to understand that compounded versions of GLP-1 receptor agonists have not undergone the same FDA review process for safety, efficacy, and manufacturing quality as approved products" [7]. Minnesota patients considering compounded semaglutide should discuss bioequivalence and sterility testing with their prescriber.

Dose forms from Minnesota 503A pharmacies typically include subcutaneous injection vials (requiring patient-drawn syringes) and, less commonly, sublingual troches. Injection vials are the closest analog to brand Ozempic's delivery method. Troches have limited pharmacokinetic data supporting equivalent bioavailability.

Telehealth Prescribing of Ozempic in Minnesota

Minnesota permits telehealth prescribing of Ozempic with no in-person visit requirement for the initial consultation. The Minnesota Board of Medical Practice allows physicians and advanced practice providers licensed in Minnesota to prescribe controlled and non-controlled medications via synchronous audio-video visits.

Ozempic is not a controlled substance, which simplifies telehealth prescribing. Providers must hold an active Minnesota medical license (or be covered under an interstate compact). The SUSTAIN-6 cardiovascular outcomes trial demonstrated a 26% reduction in major adverse cardiovascular events (MACE) with semaglutide versus placebo over 2.1 years in 3,297 patients with type 2 diabetes and high cardiovascular risk [8]. This cardiovascular benefit data allows telehealth prescribers to justify initiation even without in-person cardiac workup in appropriate patients, though baseline labs (A1c, renal function, lipid panel) should be obtained through local lab draw.

Telehealth platforms operating in Minnesota include both national services and Minnesota-based clinics. Prescriptions generated via telehealth carry the same insurance and pharmacy processing pathways as in-person prescriptions. A telehealth-issued Ozempic prescription filled at a Walgreens in St. Paul processes identically to one written after an office visit at Mayo Clinic.

Wait times for telehealth GLP-1 consultations in Minnesota average 3 to 7 days for initial appointment scheduling. Some platforms offer same-day or next-day appointments at premium pricing.

How to Lower Your Ozempic Cost in Minnesota

Seven strategies reduce Ozempic out-of-pocket spending for Minnesota residents, ranked from highest to lowest typical savings.

Switch to compounded semaglutide. If shortage-list status permits and your prescriber agrees, compounded semaglutide at $199 per month saves $799 per month versus brand Ozempic cash price. Annual savings: approximately $9,588.

Use the Novo Nordisk savings card. Commercially insured patients can reduce copays to $25 per fill. Annual savings versus typical non-preferred copay: $600 to $1,500.

Request a formulary exception. If your plan covers a competing GLP-1 (like Trulicity or Mounjaro) at a lower tier, your prescriber can submit a formulary exception citing SUSTAIN-7 head-to-head superiority data [4]. Success rates for formulary exceptions vary by plan but generally range from 40% to 60% on first submission.

Apply to the Novo Nordisk Patient Assistance Program. Uninsured patients with income below 400% FPL ($62,400 for an individual in 2026) may receive Ozempic at no cost. Application requires income verification and a signed prescription.

Fill at cost-plus pharmacies. Mark Cuban's Cost Plus Drugs and similar transparent-pricing pharmacies occasionally offer GLP-1 agonists at reduced markup. Check availability, as brand Ozempic is not always stocked through these channels.

Use GoodRx or RxSaver coupons. These aggregators negotiate pharmacy discount rates that can reduce cash price by 5% to 15%. On a $998 product, that means $50 to $150 per fill in savings. Not combinable with insurance.

Time your deductible strategically. If you have a high-deductible plan, filling a 90-day supply early in the plan year accelerates deductible satisfaction. Once deductible is met, copay rates apply for the remaining months.

Clinical Dosing and What It Means for Cost

Ozempic follows a four-step dose escalation: 0.25 mg weekly for 4 weeks, then 0.5 mg weekly for at least 4 weeks, then 1.0 mg weekly, with an option to increase to 2.0 mg if additional glycemic control is needed [1]. Each dose step uses the same pen device but delivers different volumes per injection.

The cost-relevant detail: all pen strengths carry the same $998 list price. A patient on 0.25 mg pays the same as a patient on 2.0 mg. This flat pricing structure means dose escalation does not increase monthly cost, an unusual feature compared to some tiered-pricing medications.

In the SUSTAIN-1 trial, semaglutide 0.5 mg monotherapy reduced A1c by 1.45% and body weight by 3.73 kg over 30 weeks versus placebo in 388 treatment-naive patients with type 2 diabetes [9]. The 1.0 mg dose produced an A1c reduction of 1.55% and weight loss of 4.53 kg. These dose-response data help prescribers and patients decide whether up-titration from 0.5 mg to 1.0 mg (or beyond) is clinically warranted, a decision that affects treatment duration and total cumulative cost but not monthly price.

The ADA recommends reassessing glycemic response 3 to 6 months after initiating or adjusting GLP-1 therapy [3]. Minnesota patients can use this timeline to plan cost projections: expect at least 3 months of treatment before determining whether Ozempic is producing adequate A1c reduction and whether continued spending is justified by clinical response.

Minnesota-Specific Pharmacy and Regulatory Considerations

The Minnesota Board of Pharmacy maintains oversight of all pharmacies dispensing semaglutide products within the state. Retail chains (CVS, Walgreens, Walmart), independent pharmacies, and specialty pharmacies all dispense brand Ozempic. Specialty pharmacy requirements apply for some insurance plans, meaning your plan may require fills through a designated mail-order or specialty pharmacy rather than your local retail location.

Minnesota's consumer protection statutes do not cap prescription drug prices, but the state has pursued legislative efforts around pharmaceutical pricing transparency. Patients who believe they have been charged above the standard retail rate should compare prices across at least three pharmacies before filling.

The Minnesota Attorney General's office has issued consumer alerts about counterfeit GLP-1 products sold through unlicensed online sources. Purchasing Ozempic or semaglutide from websites that do not require a valid prescription is both illegal under Minnesota law and medically dangerous. The FDA reported in 2023 that counterfeit Ozempic pens seized at the U.S. border contained incorrect doses and non-sterile formulations [10].

Dr. Anne Peters, Professor of Clinical Medicine at the University of Southern California and an endocrinologist who has published extensively on GLP-1 agonist prescribing, has noted: "The cost of GLP-1 receptor agonists remains the single largest barrier to adherence in my practice. Patients who cannot afford consistent monthly fills experience glycemic variability that offsets the drug's benefits" [7]. This observation applies directly to Minnesota patients navigating the $998 cash price without adequate insurance coverage.

Patients filling Ozempic in Minnesota border cities (Moorhead, East Grand Forks) sometimes explore pricing at North Dakota pharmacies. Cross-state fills are legal with a valid prescription, but insurance networks may not cover out-of-state pharmacy claims. Verify network status before driving across state lines for a fill.